Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Cardiovascular Cancer

Novartis/GSK mega-deal to prompt copycat dealmaking?

This article was originally published in Scrip

Executive Summary

It's not something you wake up to every day. After a relatively quiet holiday weekend with only rumors of a Pfizer/AstraZeneca mega-merger to liven things up (scripintelligence.com, 21 April 2014), Novartis and GlaxoSmithKline (and Eli Lilly) announced a deal that had everyone rubbing their eyes and taking a closer look (scripintelligence.com, 22 April 2014). In the words of GSK's CEO Sir Andrew Witty: "We needed the planets to align, and that's what's happened here."

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Cardiovascular Cancer
Latest Headlines

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

See All
UsernamePublicRestriction

Register

SC025115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By